全文获取类型
收费全文 | 37758篇 |
免费 | 3430篇 |
国内免费 | 717篇 |
专业分类
耳鼻咽喉 | 151篇 |
儿科学 | 5739篇 |
妇产科学 | 3551篇 |
基础医学 | 2868篇 |
口腔科学 | 376篇 |
临床医学 | 4132篇 |
内科学 | 3753篇 |
皮肤病学 | 160篇 |
神经病学 | 1618篇 |
特种医学 | 874篇 |
外科学 | 2900篇 |
综合类 | 4443篇 |
现状与发展 | 3篇 |
一般理论 | 4篇 |
预防医学 | 6341篇 |
眼科学 | 386篇 |
药学 | 3001篇 |
24篇 | |
中国医学 | 819篇 |
肿瘤学 | 762篇 |
出版年
2023年 | 659篇 |
2022年 | 807篇 |
2021年 | 1594篇 |
2020年 | 1438篇 |
2019年 | 1618篇 |
2018年 | 1415篇 |
2017年 | 1560篇 |
2016年 | 1502篇 |
2015年 | 1448篇 |
2014年 | 2523篇 |
2013年 | 3089篇 |
2012年 | 2151篇 |
2011年 | 2439篇 |
2010年 | 1853篇 |
2009年 | 1780篇 |
2008年 | 1825篇 |
2007年 | 1883篇 |
2006年 | 1619篇 |
2005年 | 1403篇 |
2004年 | 1135篇 |
2003年 | 980篇 |
2002年 | 818篇 |
2001年 | 662篇 |
2000年 | 583篇 |
1999年 | 485篇 |
1998年 | 413篇 |
1997年 | 339篇 |
1996年 | 367篇 |
1995年 | 303篇 |
1994年 | 320篇 |
1993年 | 233篇 |
1992年 | 232篇 |
1991年 | 205篇 |
1990年 | 199篇 |
1989年 | 170篇 |
1988年 | 171篇 |
1987年 | 135篇 |
1986年 | 141篇 |
1985年 | 221篇 |
1984年 | 208篇 |
1983年 | 132篇 |
1982年 | 157篇 |
1981年 | 103篇 |
1980年 | 107篇 |
1979年 | 92篇 |
1978年 | 78篇 |
1977年 | 64篇 |
1976年 | 60篇 |
1975年 | 29篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
随着医疗救治水平的不断提高,早产儿的存活率明显增加,但早产常易伴发脑性瘫痪、运动和认知障碍等一系列神经发育问题,给家庭、社会带来沉重负担。生命早期大脑发育迅速,可塑性强,是进行早期运动干预的良好时机。本文就早产儿早期神经运动干预进行综述,旨在为临床医护人员对早产儿进行适宜有效的运动干预提供参考。 相似文献
2.
3.
目的 探讨新生儿肺部超声在早产儿肺部感染评价中的价值。
方法 选取肺部感染早产儿80例为观察组,无肺部感染的早产儿80例为对照组,均给予新生儿肺部超声检查,比较2组肺部超声评分、氧合指数、呼吸指数,比较观察组不同病情、预后患儿肺部超声评分、氧合指数、呼吸指数,分析肺部超声评分和氧合指数、呼吸指数的相关性。
结果 观察组肺部超声评分、氧合指数低于对照组,呼吸指数高于对照组,差异有统计学意义(P<0.05)。观察组极危重患儿肺部超声评分、氧合指数低于危重和非危重患儿,呼吸指数高于危重和非危重患儿,危重患儿肺部超声评分、氧合指数低于非危重患儿,呼吸指数高于非危重患儿,差异有统计学意义(P<0.05)。肺部超声评分与呼吸指数呈负相关(r=-0.455,P<0.05),与氧合指数呈正相关(r=0.470,P<0.05)。观察组死亡患儿肺部超声评分、氧合指数低于存活患儿,呼吸指数高于存活患儿,差异有统计学意义(P<0.05)。肺部超声评分预测患儿预后的ROC曲线下面积为0.874,高于呼吸指数和氧合指数(P<0.05),其截断值为20分时,敏感度和特异度为88.50%和75.00%。
结论 新生儿肺部超声在早产儿肺部感染评价中有较好的效果,值得临床使用。 相似文献
4.
《Clínica e investigación en ginecología y obstetricia》2022,49(2):100734
Acute myeloid leukaemia (AML) is one of the deadliest haematological malignancies. During pregnancy it is a rare comorbidity and can lead to adverse outcomes, such as death, without adequate treatment. The management of AML during pregnancy remains a challenge. We report the case of a primigravida 34-year-old, with 18 weeks of amenorrhoea, who attended the emergency department presenting with pain and hypertrophy of the oral mucosa, accompanied by intense asthenia. Acute myeloblastic leukaemia was diagnosed. The possibility of terminating the pregnancy was offered given the lack of evidence regarding the maternal-foetal outcome, but the patient rejected it, so chemotherapy treatment was started. In the ultrasound controls there was no evidence of teratogenic alterations nor foetal growth restriction, and there were no alterations in Doppler flow values. It was decided to end the pregnancy at 32 + 3 GW. A preterm male was born through eutocic delivery with a normal Apgar test and umbilical cord pH, and did not require resuscitation. The puerperium was favourable and 15 days following discharge she was admitted for a bone marrow transplant from her HLA identical sister. The patient died due to rejection of the transplant and the complications derived from this event. 相似文献
5.
《Vaccine》2022,40(6):904-911
BackgroundGSK initiated a Pregnancy Registry in the United States (US) for the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap; Boostrix, GSK) vaccine with the aim to detect and describe pregnancy outcomes in women vaccinated with Boostrix 28 days before estimated conception or during pregnancy.MethodsVoluntary reports of pregnancy exposure to Boostrix received from spontaneous and post-marketing surveillance sources in the US were assessed. Reports were classified as prospective or retrospective based on the knowledge of pregnancy outcomes at the time of reporting. For completeness, reports of exposure to Boostrix or to the Tdap-inactivated poliovirus vaccine (Boostrix-IPV, GSK) reported to the global safety database from countries outside the US were also evaluated.ResultsFrom May 2005 to August 2019, 1517 (1455 prospective and 62 retrospective) pregnancy reports were received in the Boostrix US Pregnancy Registry. Of the prospective reports, 250 had known outcomes: 244 live infants with no apparent birth defects (BDs), three live infants with BDs, and three spontaneous abortions with no apparent BDs. Of the retrospective reports, 55 had known outcomes: 33 live infants with no apparent BDs, 16 live infants with BDs, one spontaneous abortion with no apparent BDs, four stillbirths with no apparent BDs, and one stillbirth with BDs. Cumulatively, 1321 pregnancy reports (1006 for Boostrix; 315 for Boostrix-IPV) were received from countries outside the US. Of these, 163 prospective reports and 551 retrospective reports had known outcomes. Results were in line with those from the Boostrix US Pregnancy Registry.ConclusionsData currently available from the Boostrix US Pregnancy Registry and from countries outside the US suggested that exposure to Boostrix or Boostrix-IPV during pregnancy does not raise safety concerns related to adverse pregnancy outcomes or BDs. 相似文献
6.
7.
《Health & place》2022
This study aimed to understand the perceived effects of the COVID-19 pandemic on physical activity, recreation walking, and use of recreational facilities; and if the COVID-19 pandemic amplified disparities in physical activity, recreational walking, and use of recreational facilities related to the levels of neighborhood disadvantage. Recreational walking and the use of neighborhood streets and green spaces significantly decreased in high deprivation areas but not in low deprivation areas during the pandemic. While COVID-19 has negatively affected overall recreational activities, the inequitable impact on recreational walking and use of outdoor recreational facilities has been more evident in disadvantaged neighborhoods with greater deprivation. 相似文献
8.
目的 探讨玻璃体腔内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗早产儿视网膜病(retinopathy of prematurity,ROP)的效果及复发的危险因素。 方法 回顾性收集2016年1月—2021年12月在郑州大学第一附属医院出生行抗VEGF治疗的ROP患儿159例的临床资料,根据首次抗VEGF治疗后随访周期内ROP复发与否分为复发组(24例)和非复发组(135例),比较分析2组临床资料,采用多因素logistic回归分析探讨抗VEGF治疗ROP复发的危险因素。 结果 经单次抗VEGF治疗后,所有159例患儿均显示附加病变消退。24例(15.1%)抗VEGF治疗后复发,复发平均时间为治疗后(8.4±2.6)周。多因素logistic回归分析显示,术前眼底出血、总用氧时间较长是ROP复发的危险因素(P <0.05),而妊娠高血压是保护因素(P <0.05)。 结论 玻璃体腔内注射抗VEGF治疗ROP是有效的。术前眼底出血和氧疗时间较长可增加ROP复发的风险,而对于妊娠高血压对ROP复发的影响,还需进一步研究证实。 相似文献
9.
10.
The retrospective study for effectiveness of cervical cerclage in preventing recurrent preterm birth
《Taiwanese journal of obstetrics & gynecology》2022,61(1):63-69
ObjectiveThis study aimed to clarify the effectiveness of cervical cerclage in preventing recurrent preterm births.Materials and methodsA retrospective study was conducted using the perinatal registration database of the Japan Society of Obstetrics and Gynecology for the Perinatal Center from 2014 to 2016. The efficacies of history-indicated, ultrasound-indicated, and physical examination-indicated cerclage as preventive treatments for women with a history of preterm birth were evaluated by comparing cerclage and non-cerclage cases. Fisher's exact test was performed to evaluate any significant differences in patient backgrounds. Prior to the evaluation, propensity score matching was performed for history-indicated and ultrasound-indicated cerclage patients.ResultsFor this study, 6060 multiparous women with a history of preterm birth were reviewed. After excluding 17 patients with unknown indications for cervical cerclage, 6043 patients were included in the study. History-indicated and ultrasound-indicated cerclage did not reduce the risk of preterm birth in subsequent pregnancies for any of the pregnancy periods (p = 0.413, p = 1.000). In contrast, physical examination-indicated cerclage significantly reduced the risk of subsequent preterm births for all pregnancy periods (p < 0.001).ConclusionSubsequent preterm births were effectively prevented only in physical examination-indicated cerclage cases. For history- or ultrasound-indicated cerclage, statistically significant differences in subsequent preterm births were not evident. 相似文献